Operating
Net Income
Alnylam Pharmaceuticals Net Income increased by 84.7% to $205.99M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1228.7%, from -$18.25M to $205.99M. Over 4 years (FY 2021 to FY 2025), Net Income shows an upward trend with a -24.4% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
Metric ID:
net_income_cfHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$189.56M | -$204.51M | -$258.46M | -$240.34M | -$277.40M | -$405.92M | -$207.49M | -$174.10M | -$276.02M | $147.75M | -$137.87M | -$65.94M | -$16.89M | -$111.57M | -$83.76M | -$18.25M | -$66.28M | $251.08M | $111.54M | $205.99M |
| QoQ Change | — | -7.9% | -26.4% | +7.0% | -15.4% | -46.3% | +48.9% | +16.1% | -58.5% | +153.5% | -193.3% | +52.2% | +74.4% | -560.6% | +24.9% | +78.2% | -263.1% | +478.8% | -55.6% | +84.7% |
| YoY Change | — | — | — | — | -46.3% | -98.5% | +19.7% | +27.6% | +0.5% | +136.4% | +33.6% | +62.1% | +93.9% | -175.5% | +39.2% | +72.3% | -292.4% | +325.0% | +233.2% | >999% |
Range-$405.92M – $251.08M
CAGR+1.8%
Avg YoY Growth+103.7%
Median YoY Growth+36.4%
Net Income at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's net income?
- Alnylam Pharmaceuticals (ALNY) reported net income of $205.99M in Q1 2026.
- How has Alnylam Pharmaceuticals's net income changed year-over-year?
- Alnylam Pharmaceuticals's net income increased by 1228.7% year-over-year, from -$18.25M to $205.99M.
- What is the long-term trend for Alnylam Pharmaceuticals's net income?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's net income has grown at a -24.4% compound annual growth rate (CAGR), from -$852.82M to $278.10M.